Heterogeneity of Cortical Lesion Susceptibility Mapping in Multiple Sclerosis

References

1. 1.↵
   2. Calabrese M,
   3. Magliozzi R,
   4. Ciccarelli O, et al

   . Exploring the origins of grey matter damage in multiple sclerosis. Nat Rev Neurosci 2015;16:147–58 doi:10.1038/nrn3900 pmid:25697158

   CrossRefPubMed
2. 2.↵
   2. Lassmann H

   . Multiple sclerosis: lessons from molecular neuropathology. Exp Neurol 2014;262(pt A):2–7 doi:10.1016/j.expneurol.2013.12.003 pmid:2434202

   CrossRefPubMed
3. 3.↵
   2. Magliozzi R,
   3. Howell O,
   4. Vora A, et al

   . Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 2007;130:1089–104 pmid:17438020

   Abstract/FREE Full Text
4. 4.↵
   2. Calabrese M,
   3. Atzori M,
   4. Bernardi V, et al

   . Cortical atrophy is relevant in multiple sclerosis at clinical onset. J Neurol 2007;254:1212–20 pmid:17361339

   CrossRefPubMedWeb of Science
5. 5.↵
   2. Calabrese M,
   3. Poretto V,
   4. Favaretto A, et al

   . Cortical lesion load associates with progression of disability in multiple sclerosis. Brain 2012;135:2952–61 doi:10.1093/brain/aws246 pmid:23065788

   Abstract/FREE Full Text
6. 6.↵
   2. Brink BP,
   3. Veerhuis R,
   4. Breij EC, et al

   . The pathology of multiple sclerosis is location-dependent: no significant complement activation is detected in purely cortical lesions. J Neuropathol Exp Neurol 2005;64:147–55 doi:10.1093/jnen/64.2.147 pmid:15751229

   CrossRefPubMed
7. 7.↵
   2. van Horssen J,
   3. Brink BP,
   4. de Vries HE, et al

   . The blood-brain barrier in cortical multiple sclerosis lesions. J Neuropathol Exp Neurol 2007;66:321–28 doi:10.1097/nen.0b013e318040b2de pmid:17413323

   Abstract/FREE Full Text
8. 8.↵
   2. Peterson JW,
   3. Bö L,
   4. Mörk S, et al

   . Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol 2001;50:389–400 doi:10.1002/ana.1123 pmid:11558796

   CrossRefPubMedWeb of Science
9. 9.↵
   2. Lucchinetti CF,
   3. Popescu BFG,
   4. Bunyan RF, et al

   . Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med 2011;365:2188–97 doi:10.1056/NEJMoa1100648 pmid:22150037

   CrossRefPubMedWeb of Science
10. 10.↵
    2. Pitt D,
    3. Boster A,
    4. Pei W, et al

    . Imaging cortical lesions in multiple sclerosis with ultra-high-field magnetic resonance imaging. Arch Neurol 2010;67:812–18 doi:10.1001/archneurol.2010.148 pmid:20625086

    CrossRefPubMedWeb of Science
11. 11.↵
    2. Li X,
    3. Harrison DM,
    4. Liu H, et al

    . Magnetic susceptibility contrast variations in multiple sclerosis lesions. J Magn Reson Imaging 2016;43:463–73 doi:10.1002/jmri.24976 pmid:26073973

    CrossRefPubMed
12. 12.↵
    2. Kooi EJ,
    3. Strijbis EM,
    4. van der Valk P, et al

    . Heterogeneity of cortical lesions in multiple sclerosis: clinical and pathologic implications. Neurology 2012;79:1369–76 doi:10.1212/WNL.0b013e31826c1b1c pmid:22972651

    Abstract/FREE Full Text
13. 13.↵
    2. Yao B,
    3. Hametner S,
    4. van Gelderen P, et al

    . 7 Tesla magnetic resonance imaging to detect cortical pathology in multiple sclerosis. PLoS One 2014;9:e108863 doi:10.1371/journal.pone.0108863 pmid:25303286

    CrossRefPubMed
14. 14.↵
    2. Deistung A,
    3. Rauscher A,
    4. Sedlacik J, et al

    . Susceptibility weighted imaging at ultra high magnetic field strengths: theoretical considerations and experimental results. Magn Reson Med 2008;60:1155–68 doi:10.1002/mrm.21754 pmid:18956467

    CrossRefPubMedWeb of Science
15. 15.↵
    2. Haacke EM,
    3. Xu Y,
    4. Cheng YC, et al

    . Susceptibility weighted imaging (SWI). Magn Reson Med 2004;52:612–18 doi:10.1002/mrm.20198 pmid:15334582

    CrossRefPubMedWeb of Science
16. 16.↵
    2. Li TQ,
    3. van Gelderen P,
    4. Merkle H, et al

    . Extensive heterogeneity in white matter intensity in high-resolution T2*-weighted MRI of the human brain at 7.0 T. Neuroimage 2006;32:1032–40 doi:10.1016/j.neuroimage.2006.05.053 pmid:16854600

    CrossRefPubMedWeb of Science
17. 17.↵
    2. Hammond KE,
    3. Metcalf M,
    4. Carvajal L, et al

    . Quantitative in vivo magnetic resonance imaging of multiple sclerosis at 7 Tesla with sensitivity to iron. Ann Neurol 2008;64:707–13 doi:10.1002/ana.21582 pmid:19107998

    CrossRefPubMedWeb of Science
18. 18.↵
    2. Hagemeier J,
    3. Weinstock-Guttman B,
    4. Bergsland N, et al

    . Iron deposition on SWI-filtered phase in the subcortical deep gray matter of patients with clinically isolated syndrome may precede structure-specific atrophy. AJNR Am J Neuroradiol 2012;33:1596–601 doi:10.3174/ajnr.A3030 pmid:22460343

    Abstract/FREE Full Text
19. 19.↵
    2. de Rochefort L,
    3. Liu T,
    4. Kressler B, et al

    . Quantitative susceptibility map reconstruction from MR phase data using Bayesian regularization: validation and application to brain imaging. Magn Reson Med 2010;63:194–206 doi:10.1002/mrm.22187 pmid:19953507

    CrossRefPubMed
20. 20.↵
    2. Langkammer C,
    3. Liu T,
    4. Khalil M, et al

    . Quantitative susceptibility mapping in multiple sclerosis. Radiology 2013;267:551–59 doi:10.1148/radiol.12120707 pmid:23315661

    CrossRefPubMedWeb of Science
21. 21.↵
    2. Chen W,
    3. Gauthier SA,
    4. Gupta A, et al

    . Quantitative susceptibility mapping of multiple sclerosis lesions at various ages. Radiology 2014;271:183–92 doi:10.1148/radiol.13130353 pmid:24475808

    CrossRefPubMed
22. 22.↵
    2. Bian W,
    3. Tranvinh E,
    4. Tourdias T, et al

    . In vivo 7T MR quantitative susceptibility mapping reveals opposite susceptibility contrast between cortical and white matter lesions in multiple sclerosis. AJNR Am J Neuroradiol 2016 Jun 9. [Epub ahead of print] doi:10.3174/ajnr.A4830 pmid:27282860

    Abstract/FREE Full Text
23. 23.↵
    2. Howell OW,
    3. Reeves CA,
    4. Nicholas R, et al

    . Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. Brain 2011;134:2755–71 doi:10.1093/brain/awr182 pmid:21840891

    Abstract/FREE Full Text
24. 24.↵
    2. Reynolds R,
    3. Roncaroli F,
    4. Nicholas R, et al

    . The neuropathological basis of clinical progression in multiple sclerosis. Acta Neuropathol 2011;122:155–70 doi:10.1007/s00401-011-0840-0 pmid:21626034

    CrossRefPubMedWeb of Science
25. 25.↵
    2. Polman CH,
    3. Reingold SC,
    4. Banwell B, et al

    . Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011;69:292–302 doi:10.1002/ana.22366 pmid:21387374

    CrossRefPubMedWeb of Science
26. 26.↵
    2. Kurtzke JF

    . Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 1983;33:1444–52 doi:10.1212/WNL.33.11.1444 pmid:6685237

    Abstract/FREE Full Text
27. 27.↵
    2. Langkammer C,
    3. Bredies K,
    4. Poser BA, et al

    . Fast quantitative susceptibility mapping using 3D EPI and total generalized variation. Neuroimage 2015;111:622–30 doi:10.1016/j.neuroimage.2015.02.041 pmid:25731991

    CrossRefPubMed
28. 28.↵
    2. Geurts JJ,
    3. Roosendaal SD,
    4. Calabrese M, et al

    ; MAGNIMS Study Group. Consensus recommendations for MS cortical lesion scoring using double inversion recovery MRI. Neurology 2011;76:418–24 doi:10.1212/WNL.0b013e31820a0cc4 pmid:21209373

    Abstract/FREE Full Text
29. 29.↵
    2. Avants BB,
    3. Tustison NJ,
    4. Wu J, et al

    . An open source multivariate framework for n-tissue segmentation with evaluation on public data. Neuroinformatics 2011;9:381–400 doi:10.1007/s12021-011-9109-y pmid:21373993

    CrossRefPubMedWeb of Science
30. 30.↵
    2. Calabrese M,
    3. Castellaro M,
    4. Bertoldo A, et al

    . Epilepsy in multiple sclerosis: the role of temporal lobe damage. Mult Scler 2016 Jun 3. [Epub ahead of print] doi:10.1177/1352458516651502 pmid:27260699

    CrossRefPubMed
31. 31.↵
    2. Zhang Y,
    3. Gauthier SA,
    4. Gupta A, et al

    . Longitudinal change in magnetic susceptibility of new enhanced multiple sclerosis (MS) lesions measured on serial quantitative susceptibility mapping (QSM). J Magn Reson Imaging 2016;44:426–32 doi:10.1002/jmri.25144 pmid:26800367

    CrossRefPubMed
32. 32.↵
    2. Zhang Y,
    3. Gauthier SA,
    4. Gupta A, et al

    . Quantitative susceptibility mapping and R2* measured changes during white matter lesion development in multiple sclerosis: myelin breakdown, myelin debris degradation and removal, and iron accumulation. AJNR Am J Neuroradiol 2016;37:1629–35 doi:10.3174/ajnr.A4825 pmid:27256856

    Abstract/FREE Full Text
33. 33.↵
    2. Zhang Y,
    3. Gauthier SA,
    4. Gupta A, et al

    . Magnetic susceptibility from quantitative susceptibility mapping can differentiate new enhancing from nonenhancing multiple sclerosis lesions without gadolinium injection. AJNR Am J Neuroradiol 2016 Jun 30. [Epub ahead of print] doi:10.3174/ajnr.A4856 pmid:27365331

    Abstract/FREE Full Text
34. 34.↵
    2. Kidd D,
    3. Barkhof F,
    4. McConnell R, et al

    . Cortical lesions in multiple sclerosis. Brain 1999;122 (pt 1):17–26 doi:10.1093/brain/122.1.17 pmid:10050891

    Abstract/FREE Full Text
35. 35.↵
    2. Peruzzo D,
    3. Castellaro M,
    4. Calabrese M, et al

    . Heterogeneity of cortical lesions in multiple sclerosis: an MRI perfusion study. J Cereb Blood Flow Metab 2013;33:457–63 doi:10.1038/jcbfm.2012.192 pmid:23250108

    CrossRefPubMed
36. 36.↵
    2. Seewann A,
    3. Vrenken H,
    4. Kooi E-J, et al

    . Imaging the tip of the iceberg: visualization of cortical lesions in multiple sclerosis. Mult Scler J 2011;17:1202–10 doi:10.1177/1352458511406575 pmid:21561955

    CrossRefPubMed
37. 37.↵
    2. Sethi V,
    3. Yousry TA,
    4. Muhlert N, et al

    . Improved detection of cortical MS lesions with phase-sensitive inversion recovery MRI. J Neurol Neurosurg Psychiatry 2012;83:877–82 doi:10.1136/jnnp-2012-303023 pmid:22807559

    Abstract/FREE Full Text
38. 38.↵
    2. Wharton S,
    3. Bowtell R

    . Fiber orientation-dependent white matter contrast in gradient echo MRI. Proc Natl Acad Sci U S A 2012;109:18559–64 doi:10.1073/pnas.1211075109 pmid:23091011

    Abstract/FREE Full Text
39. 39.↵
    2. Bagnato F,
    3. Hametner S,
    4. Yao B, et al

    . Tracking iron in multiple sclerosis: a combined imaging and histopathological study at 7 Tesla. Brain 2011;134(pt 12):3602–15 doi:10.1093/brain/awr278 pmid:22171355

    Abstract/FREE Full Text
40. 40.↵
    2. Yao B,
    3. Bagnato F,
    4. Matsuura E, et al

    . Chronic multiple sclerosis lesions: characterization with high-field-strength MR imaging. Radiology 2012;262:206–15 doi:10.1148/radiol.11110601 pmid:22084205

    CrossRefPubMedWeb of Science
41. 41.↵
    2. Langkammer C,
    3. Krebs N,
    4. Goessler W, et al

    . Quantitative MR imaging of brain iron: a postmortem validation study. Radiology 2010;257:455–62 doi:10.1148/radiol.10100495 pmid:20843991

    CrossRefPubMedWeb of Science
42. 42.↵
    2. Lee J,
    3. Shmueli K,
    4. Kang BT, et al

    . The contribution of myelin to magnetic susceptibility-weighted contrasts in high-field MRI of the brain. Neuroimage 2012;59:3967–75 doi:10.1016/j.neuroimage.2011.10.076 pmid:22056461

    CrossRefPubMedWeb of Science
43. 43.↵
    2. Li W,
    3. Wu B,
    4. Liu C

    . Quantitative susceptibility mapping of human brain reflects spatial variation in tissue composition. Neuroimage 2011;55:1645–56 doi:10.1016/j.neuroimage.2010.11.088 pmid:21224002

    CrossRefPubMedWeb of Science
44. 44.↵
    2. Schweser F,
    3. Deistung A,
    4. Lehr BW, et al

    . Quantitative imaging of intrinsic magnetic tissue properties using MRI signal phase: an approach to in vivo brain iron metabolism? Neuroimage 2011;54:2789–807 doi:10.1016/j.neuroimage.2010.10.070 pmid:21040794

    CrossRefPubMedWeb of Science
45. 45.↵
    2. Langkammer C,
    3. Schweser F,
    4. Krebs N, et al

    . Quantitative susceptibility mapping (QSM) as a means to measure brain iron? A post mortem validation study. Neuroimage 2012;62:1593–99 doi:10.1016/j.neuroimage.2012.05.049 pmid:22634862

    CrossRefPubMed
46. 46.↵
    2. Li W,
    3. Wu B,
    4. Avram AV, et al

    . Magnetic susceptibility anisotropy of human brain in vivo and its molecular underpinnings. Neuroimage 2012;59:2088–97 doi:10.1016/j.neuroimage.2011.10.038 pmid:22036681

    CrossRefPubMedWeb of Science
47. 47.↵
    2. Kutzelnigg A,
    3. Lucchinetti CF,
    4. Stadelmann C, et al

    . Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 2005;128:2705–12 doi:10.1093/brain/awh641 pmid:16230320

    Abstract/FREE Full Text
48. 48.↵
    2. Craelius W,
    3. Migdal MW,
    4. Luessenhop CP, et al

    . Iron deposits surrounding multiple sclerosis plaques. Arch Pathol Lab Med 1982;106:397–99 pmid:6896630

    PubMedWeb of Science
49. 49.↵
    2. Bagnato F,
    3. Ikonomidou VN,
    4. van Gelderen P, et al

    . Lesions by tissue specific imaging characterize multiple sclerosis patients with more advanced disease. Mult Scler 2011;17:1424–31 doi:10.1177/1352458511414601 pmid:21803873

    CrossRefPubMed
50. 50.↵
    2. Kakeda S,
    3. Futatsuya K,
    4. Ide S, et al

    . Improved detection of cortical gray matter involvement in multiple sclerosis with quantitative susceptibility mapping. Acad Radiol 2015;22:1427–32 doi:10.1016/j.acra.2015.08.003 pmid:26342769

    CrossRefPubMed
51. 51.↵
    2. Stüber C,
    3. Pitt D,
    4. Wang Y

    . Iron in multiple sclerosis and its noninvasive imaging with quantitative susceptibility mapping. Int J Mol Sci 2016;17(1) doi:10.3390/ijms17010100 pmid:26784172

    CrossRefPubMed
52. 52.↵
    2. Hametner S,
    3. Wimmer I,
    4. Haider L, et al

    . Iron and neurodegeneration in the multiple sclerosis brain. Ann Neurol 2013;74:848–61 doi:10.1002/ana.23974 pmid:23868451

    CrossRefPubMed
53. 53.↵
    2. Paling D,
    3. Tozer D,
    4. Wheeler-Kingshott C, et al

    . Reduced R2′ in multiple sclerosis normal appearing white matter and lesions may reflect decreased myelin and iron content. J Neurol Neurosurg Psychiatry 2012;83:785–92 doi:10.1136/jnnp-2012-302541 pmid:22626944

    Abstract/FREE Full Text
54. 54.↵
    2. Khalil M,
    3. Langkammer C,
    4. Pichler A, et al

    . Dynamics of brain iron levels in multiple sclerosis: a longitudinal 3T MRI study. Neurology 2015;84:2396–402 doi:10.1212/WNL.0000000000001679 pmid:25979698

    CrossRefPubMed
55. 55.↵
    2. Schenck JF,
    3. Zimmerman EA

    . High-field magnetic resonance imaging of brain iron: birth of a biomarker? NMR Biomed 2004;17:433–45 doi:10.1002/nbm.922 pmid:15523705

    CrossRefPubMedWeb of Science
56. 56.↵
    2. Calabrese M,
    3. Reynolds R,
    4. Magliozzi R, et al

    . Regional distribution and evolution of gray matter damage in different populations of multiple sclerosis patients. PLoS One 2015;10:e0135428 doi:10.1371/journal.pone.0135428 pmid:26267665

    CrossRefPubMed
57. 57.↵
    2. Trapp BD,
    3. Wujek JR,
    4. Criste GA, et al

    . Evidence for synaptic stripping by cortical microglia. Glia 2007;55:360–68 doi:10.1002/glia.20462 pmid:17136771

    CrossRefPubMedWeb of Science